Kaiser Foundation Health Plan dramatically ramped up its lobbying efforts in Q1 2025, spending $3.06 million to influence legislation on healthcare affordability and the federal budget — a staggering 1260% increase from the previous quarter.
Why it matters: The massive spending surge signals Kaiser’s strategic prioritization of protecting and expanding the Affordable Care Act marketplace subsidies while influencing Medicare and Medicaid funding through budget resolutions.
By the numbers:
- $3,000,000 spent on in-house lobbying (up from $220,000 in Q4 2024)
- $60,000 paid to Bluestone Strategies LLC, maintaining a consistent relationship dating back to 2020
The focus: Kaiser’s lobbying efforts target several key pieces of legislation:
- Health Care Affordability Act of 2025 (H.R. 247/S. 46) — Would expand eligibility for Advance Premium Tax Credits for ACA marketplace coverage
- House and Senate budget resolutions establishing government funding for FY2025 — Critical for Medicare and Medicaid program funding
Behind the effort: Kaiser relies on an experienced lobbying team with deep healthcare policy expertise:
- Laird D. Burnett — Kaiser’s most tenured lobbyist with activity dating back to 1999, providing institutional knowledge
- Mary Prudence Fitzpatrick — Former Blue Cross Blue Shield Association lobbyist and Legislative Assistant to Senator Michael Bennet
- David C. Bennett — Former Legislative Assistant to Senator Mitch McConnell, bringing Republican insights
The competitive landscape: Kaiser isn’t alone in lobbying on these issues. Other major players include:
- Health insurers: Highmark, BlueCross BlueShield of Tennessee, AHIP
- Hospital systems: Federation of American Hospitals ($1M in lobbying), Ascension
- Patient advocacy: American Cancer Society Cancer Action Network ($1.98M in lobbying)
Between the lines: The Health Care Affordability Act has garnered significant Democratic support, including 41 original Senate cosponsors, but remains in committee in both chambers. Meanwhile, budget resolution debates reveal partisan divides over healthcare program funding.
The bottom line: Kaiser’s dramatic lobbying escalation reflects the high stakes for health insurers as Congress debates the future of ACA subsidies and government healthcare programs. The company clearly sees these issues as mission-critical to its business model and market strategy.
Spot something wrong? Report an issue with this article